CA
NZ
UK
AU
IND
US
Holley Inc. filed a Form 8-K with the SEC on August 5, 2026, announcing its financial results and operational highlights for the quarter ended June 28, 2026, along with full-year 2026 outlook and guidance.
MGE Energy, Inc. and its subsidiary Madison Gas and Electric Company filed a current report with the SEC on August 5, 2026, announcing second quarter 2026 earnings results and posting a financial presentation to the company's Investor Relations website.
Royalty Pharma plc filed a Current Report on Form 8-K with the SEC on August 5, 2026, announcing the issuance of a press release covering its financial results for the quarter ended June 30, 2026.
Plumas Bancorp filed its quarterly report on Form 10-Q with the SEC on August 5, 2026, covering the period ended June 30, 2026, disclosing condensed consolidated financial statements for the three and six months ended on that date.
Ponce Financial Group, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, reporting second-quarter and year-to-date financial results for the period.
Precigen (NASDAQ:PGEN) is a Germantown, Maryland-based biopharmaceutical company advancing next-generation gene and cell therapies to address serious diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company leverages proprietary precision technology platforms, including UltraCAR-T, AdenoVerse, ActoBiotics, and UltraVector, to design, engineer, and manufacture differentiated …
Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by its proprietary Native Complex Platform. Founded in 2019 and formerly known as GPCR NewCo, the company …
Twist Bioscience (NASDAQ:TWST) is a South San Francisco-based synthetic biology company founded in 2013 that has developed a proprietary silicon-based DNA synthesis platform, enabling high-throughput, cost-effective manufacturing of synthetic DNA at unprecedented precision and scale. The company offers a broad portfolio of products and …
UroGen Pharma (NASDAQ:URGN) is a Princeton, New Jersey-based biotechnology company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, leveraging its proprietary RTGel reverse-thermal hydrogel technology platform that enables sustained, site-specific delivery of chemotherapy agents. The company's commercial portfolio includes JELMYTO, …
ACADIA Pharmaceuticals (NASDAQ:ACAD) is a San Diego-based biopharmaceutical company focused on the development and commercialization of innovative medicines targeting central nervous system disorders and rare diseases in the United States. The company markets two FDA-approved products, NUPLAZID, the first and only approved treatment for …
Please wait processing your request...